Akebia Therapeutics (AKBA) is a biopharma firm advancing antibody-drug conjugate therapies for rare diseases, recently reporting a significant year-over-year revenue rebound and improved operational cash flow.
Investors should consider AKBA as a turnaround play given the dramatic reduction in net losses and the generation of positive operating cash flow despite ongoing R&D spending. The company's exclusive focus on rare diseases offers potential for high-margin approvals with long-term commercial tailwinds from orphan drug protections. With strong cash reserves of $184.8M, Akebia has sufficient liquidity to advance its pipeline without immediate need for dilutive financing rounds.
The stock carries substantial risk due to a retained earnings deficit of $1.68B and total liabilities exceeding total equity at $344M versus $32.6M in shareholders' equity. The company has not yet achieved profitability from product sales, meaning future value depends entirely on successful clinical trials which are binary events. High operating expenses of $173.2M combined with a volatile revenue trend over the last five years suggests financial instability if clinical milestones are missed.
Akebia Therapeutics is a biopharmaceutical company focused on developing novel medicines to treat rare diseases, primarily leveraging its proprietary antibody-drug conjugate technology. The company serves markets in the United States and internationally with a pipeline targeting oncology and other therapeutic areas. Key products include candidates like AKBA-5602 designed to address unmet needs in rare disease populations.
Despite reporting a net loss of $5.3M in 2025, the company demonstrated a remarkable operational turnaround with cash flow from operations reaching $68.0M and ending cash reserves climbing to $186.5M. This improvement contrasts sharply with the prior year's revenue decline and suggests effective cost management or a strategic shift in clinical progress that reduced burn rates. The gross profit margin of 83% indicates strong pricing power or low direct manufacturing costs typical of early-stage biotech.
The biopharmaceutical sector for rare diseases is characterized by high barriers to entry, intense competition from large pharma and smaller biotechs, and a heavy reliance on successful clinical trial outcomes. Companies in this space typically operate with negative earnings until product approval, relying on venture capital or public markets for funding. Recent trends show increasing consolidation and M&A activity as larger entities seek to acquire late-stage assets from specialized developers like Akebia.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $292.6M | $194.6M | $160.2M | $236.2M |
| Cost of Revenue | $84.8M | $74.1M | $63.2M | $39.5M |
| Gross Profit | $207.8M | $120.5M | $97.0M | $196.7M |
| Operating Expenses | $286.9M | $166.7M | $147.5M | $173.2M |
| Operating Income | $-79.1M | $-46.3M | $-50.5M | $23.5M |
| R&D | $129.1M | $63.1M | $37.7M | $62.4M |
| G&A | $138.7M | $100.2M | $106.5M | $107.5M |
| Stock-Based Comp | $17.8M | $9.3M | $7.8M | $11.3M |
| D&A | $1.7M | — | — | — |
| Depreciation | $1.7M | $1.6M | $1.5M | $1.3M |
| Amortization | $36.0M | $36.0M | $36.0M | $0 |
| Other OpEx | $19.1M | $3.4M | $3.3M | $3.4M |
| Non-Operating Income | $-13.4M | $-5.7M | $-18.9M | $-27.2M |
| Pre-Tax Income | $-92.6M | $-51.9M | $-69.4M | $-3.7M |
| Income Tax | $0 | $0 | $0 | $1.6M |
| Continuing Ops | $-92.6M | $-51.9M | $-69.4M | $-5.3M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-92.6M | $-51.9M | $-69.4M | $-5.3M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-92.6M | $-51.9M | $-69.4M | $-5.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $184.9M | $118.1M | $113.8M | $253.0M |
| Cash & Equivalents | $90.5M | $42.9M | $51.9M | $184.8M |
| Accounts Receivable | $39.2M | $39.3M | $34.4M | $47.0M |
| Inventory | $21.8M | $15.7M | $16.2M | $15.6M |
| Prepaid Expenses | $33.5M | $20.2M | $11.3M | $5.5M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $166.9M | $123.6M | $106.8M | $123.6M |
| PP&E (Net) | $5.2M | $3.6M | $2.2M | $1.2M |
| Intangibles | — | $36.0M | $0 | — |
| Goodwill | $55.1M | $59.0M | $59.0M | $59.0M |
| Operating Leases | $29.2M | $12.4M | $8.2M | $3.7M |
| Other LT Assets | $77.5M | $12.4M | $37.4M | $59.7M |
| Total Assets | $351.8M | $241.7M | $220.7M | $376.6M |
| Current Liabilities | $124.8M | $99.9M | $80.9M | $162.9M |
| Accounts Payable | $18.0M | $14.6M | $15.2M | $21.2M |
| Current Debt | $32.0M | $17.5M | $0 | — |
| Current Leases | $4.7M | $4.5M | $5.4M | $3.5M |
| Deferred Revenue | $3.7M | $0 | — | $2.7M |
| Other Current Liab | $-4.7M | $-4.5M | $-3.1M | $13.8M |
| Long-Term Liabilities | $217.7M | $172.4M | $188.9M | $181.0M |
| Long-Term Debt | $34.1M | $17.2M | $38.7M | $48.2M |
| LT Operating Leases | $29.0M | $8.9M | $3.5M | $0 |
| Other LT Liab | $111.4M | $103.0M | $146.7M | $132.8M |
| Total Liabilities | $342.5M | $272.3M | $269.9M | $344.0M |
| Shareholders' Equity | $9.3M | $-30.6M | $-49.2M | $32.6M |
| Retained Earnings | $-1.55B | $-1.61B | $-1.68B | $-1.68B |
| AOCI | $6.0K | $6.0K | $6.0K | $6.0K |
| Total L&E | $351.8M | $241.7M | $220.7M | $376.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-92.6M | $-51.9M | $-69.4M | $-5.3M |
| Non-Cash Adjustments | $76.7M | $67.9M | $38.7M | $-7.8M |
| Working Capital Changes | $-57.3M | $-39.3M | $-10.0M | $81.1M |
| Cash from Operations | $-73.2M | $-23.4M | $-40.7M | $68.0M |
| Capital Expenditures | $114.0K | $0 | $33.0K | $291.0K |
| Cash from Investing | $-114.0K | $0 | $-33.0K | $-7.9M |
| Debt Issuances | $0 | — | — | — |
| Cash from Financing | $14.6M | $-25.2M | $49.7M | $72.9M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-58.7M | $-48.6M | $9.0M | $133.0M |
| Beginning Cash | $151.8M | $93.2M | $44.6M | $53.5M |
| Ending Cash | $93.2M | $44.6M | $53.5M | $186.5M |
The company's revenue is primarily driven by its oncology and rare disease therapeutic programs utilizing antibody-drug conjugates. Significant portions of the financials are allocated to high research and development expenditures aimed at advancing clinical candidates. Revenue streams also include potential collaboration income or licensing fees, though current operations are heavily weighted toward internal R&D costs.
The company faces significant cash burn risks given the substantial research and development expenses relative to its current revenue base. Regulatory approval uncertainties for its clinical candidates could delay or prevent future commercialization timelines. Reliance on successful outcomes in ongoing trials is critical as there are no approved products currently generating profit. Macroeconomic headwinds could impact access to capital required for sustaining these high-cost drug development programs.
Akebia possesses a proprietary platform for developing antibody-drug conjugates that offers targeted delivery mechanisms with potentially reduced off-target toxicity. The company's focus on rare diseases provides access to substantial government incentives like orphan drug designations and market exclusivity periods. Its specialized expertise in manufacturing complex biologics creates high barriers to entry for competitors attempting similar development pathways.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.